Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24928
Abstract: The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR‐ABL1‐positive acute myeloid leukemia (AML). Fifty‐seven patients (median age, 48 years, range: 19‐67) with BCR‐ABL1… read more here.
Keywords: abl1 positive; positive aml; transplantation; sct ... See more keywords
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26949
Abstract: Reverse transcription polymerase chain reaction (RT-PCR) for BCR::ABL1 is the most common and widely accepted method of measurable residual disease (MRD) assessment in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); however, RT-PCR may not be an… read more here.
Keywords: ngs mrd; pcr bcr; pcr; bcr abl1 ... See more keywords
BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat?
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.31848
Abstract: BCR/ABL1–like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B‐lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that… read more here.
Keywords: bcr; abl1 like; lymphoblastic leukemia; acute lymphoblastic ... See more keywords
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3002-1
Abstract: We investigated the frequency, predictors, and evolution of acute lymphoblastic leukemia (ALL) in patients with CNS relapse and introduced a novel method for studying BCR-ABL1 protein variants in cDNA from bone marrow (BM) and cerebrospinal… read more here.
Keywords: cns relapse; lymphoblastic leukemia; relapse; acute lymphoblastic ... See more keywords
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02910-6
Abstract: PurposeThe advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) recommends quantification of BCR–ABL1 transcripts by real-time quantitative PCR every 3 months during TKI treatment.… read more here.
Keywords: response; molecular response; deep molecular; kinase inhibitor ... See more keywords
Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01419-9
Abstract: BackgroundMajor BCR-ABL1 mRNA in patients with chronic myeloid leukemia (CML) has generally been analysed by real-time polymerase chain reaction (PCR). Application of the international scale (IS) for the quantification of major BCR-ABL1 mRNA has been… read more here.
Keywords: bcr; real time; pcr; abl1 mrna ... See more keywords
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01028-8
Abstract: Chronic myeloid leukemia (CML) is successfully treated with BCR-ABL1 tyrosine kinase inhibitors, but a significant percentage of patients develop resistance. Insulin receptor substrate 1 (IRS1) has been shown to constitutively associate with BCR-ABL1, and IRS1-specific… read more here.
Keywords: igf1r irs1; irs1; bcr abl1; antineoplastic effects ... See more keywords
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
Sign Up to like & getrecommendations! Published in 2019 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-019-00549-1
Abstract: Identification of the BCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite… read more here.
Keywords: bcr; cml; hidden pathogenesis; event ... See more keywords
Olverembatinib: First Approval
Sign Up to like & getrecommendations! Published in 2022 at "Drugs"
DOI: 10.1007/s40265-022-01680-9
Abstract: Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal… read more here.
Keywords: olverembatinib first; bcr abl1; cml; first approval ... See more keywords
Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2018 at "Human pathology"
DOI: 10.1016/j.humpath.2018.09.010
Abstract: Chronic myeloid leukemia is characterized by a t(9;22)(q34;q11.2) resulting in BCR/ABL1 fusion located on the derivative chromosome 22, also known as the Philadelphia chromosome. We present the first case, to our knowledge, of chronic myeloid… read more here.
Keywords: pair sequencing; myeloid leukemia; bcr abl1; chronic myeloid ... See more keywords
Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells.
Sign Up to like & getrecommendations! Published in 2020 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2020.115013
Abstract: In this study, we investigated the mechanisms underlying arsenic trioxide (ATO)-induced death of human BCR-ABL1-positive K562 and MEG-01 cells. ATO-induced apoptotic death in K562 cells was characterized by ROS-mediated mitochondrial depolarization, MCL1 downregulation, p38 MAPK… read more here.
Keywords: p38 mapk; ato induced; mapk; downregulation ... See more keywords